Mallinckrodt Pharmaceuticals

In 2024, Mallinckrodt Pharmaceuticals reported total emissions of approximately 149,135,000 kg CO2e, which includes Scope 1 emissions of about 80,934,000 kg CO2e, Scope 2 emissions of approximately 68,794,000 kg CO2e (market-based), and Scope 3 emissions, which are not fully disclosed but include significant categories such as purchased goods and services (approximately 178,886,000 kg CO2e) and upstream transportation and distribution (approximately 22,438,000 kg CO2e).

The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 30% from a 2022 baseline by 2030. Additionally, Mallinckrodt aims to achieve near-zero emissions for both Scope 1 and Scope 2 by the middle of this decade (2025). These targets reflect a proactive approach to climate action, aligning with industry standards for sustainability.

It is important to note that the emissions data for Mallinckrodt Pharmaceuticals is cascaded from its parent organization, Mallinckrodt plc, indicating a structured approach to environmental reporting within its corporate family.